Athira Pharma Inc. (ATHA) stock is nearly perfect except the valuation

The closing price of Athira Pharma Inc. (NASDAQ: ATHA) was $3.49 for the day, up 3.56% from the previous closing price of $3.37. In other words, the price has increased by $+0.1200 from its previous closing price. On the day, 688471 shares were traded. ATHA stock price reached its highest trading level at $3.6000 during the session, while it also had its lowest trading level at $3.3300.

Top 5 Undervalued Stocks To Own In 2023

Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.

Click here to download your Free Research Report…



Our analysis of ATHA’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 22.30 and its Current Ratio is at 22.30. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.

Upgrades & Downgrades

On July 07, 2022, Mizuho started tracking the stock assigning a Buy rating and target price of $6.

Stifel Downgraded its Buy to Hold on June 23, 2022, whereas the target price for the stock was revised from $36 to $5.

Insider Transactions:

Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Dec 28 when MILESON GLENNA bought 50,000 shares for $2.85 per share. The transaction valued at 142,250 led to the insider holds 159,930 shares of the business.

Romano Kelly A bought 30,000 shares of ATHA for $98,700 on Dec 02. The Director now owns 38,315 shares after completing the transaction at $3.29 per share. On Nov 15, another insider, MOEBIUS HANS, who serves as the Chief Medical Officer of the company, bought 5,000 shares for $3.29 each. As a result, the insider paid 16,442 and bolstered with 65,836 shares of the company.

Stock Price History:

Over the past 52 weeks, ATHA has reached a high of $14.22, while it has fallen to a 52-week low of $2.53. The 50-Day Moving Average of the stock is 3.2036, while the 200-Day Moving Average is calculated to be 5.0352.

Shares Statistics:

ATHA traded an average of 302.00K shares per day over the past three months and 527.61k shares per day over the past ten days. A total of 37.82M shares are outstanding, with a floating share count of 35.89M. Insiders hold about 1.10% of the company’s shares, while institutions hold 64.50% stake in the company. Shares short for ATHA as of Oct 13, 2022 were 1.83M with a Short Ratio of 1.53M, compared to 1.86M on Sep 14, 2022. Therefore, it implies a Short% of Shares Outstanding of 4.85% and a Short% of Float of 5.41%.

Earnings Estimates

The firm’s stock currently is rated by 6 analysts. On average, analysts expect EPS of -$0.63 for the current quarter, with a high estimate of -$0.57 and a low estimate of -$0.69, while EPS last year was -$0.42. The consensus estimate for the next quarter is -$0.67, with high estimates of -$0.56 and low estimates of -$0.77.

Analysts are recommending an EPS of between -$2.39 and -$2.67 for the fiscal current year, implying an average EPS of -$2.52. EPS for the following year is -$2.77, with 6 analysts recommending between -$0.57 and -$4.49.